VBIO Stock Catalyst: Tivic Health Advances Discussions on Entolimod with U.S. Defense Agency

Aug 14, 2025 · 7:59pm ET

Interest expressed at MHSRS 2025.

Max move

+95.4%

High of day $5.98

Sparker timei

7:59pm ET

VBIO · Aug 14, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Tivic Health, Inc. (Nasdaq: VBIO) announced that it has advanced discussions regarding the use of its drug candidate, Entolimod, as a radiation countermeasure. This development follows interest expressed by the U.S. Defense Agency at the Military Health System Research Symposium (MHSRS) in 2025.

The company is exploring potential collaborations and funding opportunities with the agency to further the development and testing of Entolimod for this specific application. No financial details or timelines were disclosed in the announcement.

As of the latest available data, Valion Bio, Inc. has a free float of 1,579,400 shares and 1,766,000 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time VBIO sparks.

Download Sniper App →

Catch the next VBIO-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →